1206-37-7

Usage

Uses

Used in Pharmaceutical Industry:
4-Dimethylsulfamoyl-benzoic Acid is used as an intermediate compound for the synthesis of various pharmaceuticals. Its unique chemical structure allows it to be a key component in the development of new drugs, contributing to the advancement of medical treatments.
Used in Dye Industry:
In the dye industry, 4-Dimethylsulfamoyl-benzoic Acid is utilized as an intermediate in the production of dyes. Its chemical properties enable it to be a part of the formulation process, resulting in a wide range of colorants for various applications.
Used in Organic Compounds Synthesis:
4-Dimethylsulfamoyl-benzoic Acid is employed as an intermediate in the synthesis of other organic compounds. Its versatility in chemical reactions makes it a valuable component in the creation of a diverse array of organic substances for various industrial and scientific purposes.

InChI:InChI=1/C9H11NO4S/c1-10(2)15(13,14)8-5-3-7(4-6-8)9(11)12/h3-6H,1-2H3,(H,11,12)

Upstream product

• 63877-94-1 4-cyano-N,N-dimethylbenzenesulfonamide 
• 138-41-0 4-(aminosulfonyl)-benzoic acid 
• 77-78-1 dimethyl sulfate 
• 10130-89-9 p-carboxyphenylsulfonyl chloride 
• 10486-51-8 4-ethoxycarbonylbenzenesulfonyl chloride 
• 83112-37-2 4-<(Dimethylamino)sulfonyl>benzoic Acid Ethyl Ester 
• 124-40-3 dimethyl amine 
• 599-69-9 N,N,4-trimethylbenzenesulfonamide 

Downstream Products

• 29171-70-8 4-(N,N-dimethylaminosulfonyl)benzoyl chloride 
• 857486-81-8 4-dimethylsulfamoyl-benzoic acid methylamide 
• 83112-37-2 4-<(Dimethylamino)sulfonyl>benzoic Acid Ethyl Ester 
• 53554-96-4 4-<(Dimethylamino)sulfonyl>benzoic Acid Hydrazide 
• 96134-53-1 N,N-Dimethyl-4-[1,3,4]oxadiazol-2-yl-benzenesulfonamide 
• 96134-54-2 4-(5-Methyl-1,3,4-oxadiazol-2-yl)-N,N-dimethylbenzenesulfonamide 
• 96134-55-3 4-(5-Ethyl-[1,3,4]oxadiazol-2-yl)-N,N-dimethyl-benzenesulfonamide 
• 96134-56-4 N,N-Dimethyl-4-(5-phenyl-[1,3,4]oxadiazol-2-yl)-benzenesulfonamide 
• 58804-18-5 4-hydroxymethyl-benzenesulfonic acid dimethylamide 

Relevant academic research and scientific papers

Identification of thiophene-benzenesulfonamide derivatives for the treatment of multidrug-resistant tuberculosis

A series of thiophene-benzenesulfonamide derivatives was designed and synthesized by exploring the structure-activity relationship of lead compounds 2,3-disubstituted thiophenes 25a and 297F as antituberculosis agents, which displayed potent antimycobacterial activity against drug-susceptible and clinically isolated drug-resistant tuberculosis. In particular, compound 17b, which had improved activity (minimum inhibitory concentration of 0.023 μg/mL) compared with the lead compounds, displayed good intracellular antimycobacterial activity in macrophages with a reduction of 1.29 log10 CFU. A druggability evaluation indicated that compound 17b had favorable hepatocyte stability, low cytotoxicity, and low hERG channel inhibition. Moreover, compound 17b exhibited modest in vivo efficacy in an acute mouse model of tuberculosis. In addition, the molecular docking study elucidated the binding mode of compound 17b in the active site of DprE1. Therefore, compound 17b may be a promising antituberculosis lead for further research.

Diaryl 2- amide-substituted thiophene imide ester compound as well as preparation method and application thereof (by machine translation)

The invention also discloses a 2 - synthesis method thereof, and an application of the compound as an antibacterial agent, in the phthisis-caused by the bacterium, in particular to the, mycobacterium-induced infectious disease (especially (Tuberculosis,TB), mycobacterium- induced mycobacterium, tuberculosis), and (I) the invention, specifically relates to a pharmaceutical composition containing the compound of the present invention or, a R pharmaceutical composition comprising the compound of the present invention. 1 , R2 , R3 , R4 , R5 As described Y in the present invention. as described in the specification, the present invention is directed, to the preparation of novel compounds, having an anti-mycobacterial activity as potential, new drug (s) for the treatment (TB) or preventative treatment of infectious diseases, consisting of M. tuberculosis, in particular phthisis- caused by tubercular mycobacteria, while being useful in overcoming the problems associated with drug resistance. (by machine translation)

NOVEL QUINOLINE ESTERS USEFUL FOR TREATING SKIN DISORDERS

Disclosed are quinoline esters of Formula (I): which are useful as Liver X receptors (LXR) modulators. Pharmaceutical compositions containing quinoline esters of Formula (I) and the use of quinoline esters of Formula (I) in the safe treatment of various s

Discovery of novel thieno[2,3-d]pyrimidin-4-yl hydrazone-based inhibitors of Cyclin D1-CDK4: Synthesis, biological evaluation and structure-activity relationships. Part 2

The design, synthesis and evaluation of novel thieno[2,3-d]pyrimidin-4-yl hydrazone analogues as cyclin-dependent kinase 4 (CDK4) inhibitor are described. Focusing on the optimization of the heteroaryl moiety at the hydrazone with substituted phenyl group

Factors Which Influence the Formation of Oxadiazoles from Anthranilhydrazides and Other Benzoylhydrazines

The cyclization of o-aminobenzoylhydrazine (1a) and its 5-methyl derivative 1b with four equivalents and with one equivalent of triethyl orthoacetate (TEOA) was studied. 3-Amino-2-methyl-4(3H)-quinazolinone (2a), 3,4-dihydro-2-methyl-5H-1,3,4-benzotriazepin-5-one (3a) and an imino ether derivative of 2a, N-ethanimidic acid ethyl ester (4a) were obtained from the reaction of 1a with four equivalents of TEOA.These results were compared with those of Merour who isolated 2a and 3a using the same conditions.When 1a was treated with one equivalent of TEOA, 2a, 3a, and a new product, 2-(5-methyl-1,3,4-oxadiazol-2-yl)benzenamine (5a) were produced, and 4a was not.Similar results were obtained with the reactions of 1b with TEOA.Authentic samples of oxadiazoles 5a and b were prepared by alternate routes.Novel acid-catalyzed rearrangements of benzotriazepinones 3a and b, to mixtures of aminoquinazolinones 2a and b and oxadiazoles 5a and b, respectively, were found.The different relative amounts of aminoquinazolinones 2 and oxadiazoles 5 which were produced from these rearrangements allowed us to choose between two potential mechanism for these interesting rearrangements.Treatment of 5-nitrobenzoylhydrazine (37) with four equivalents of TEOA gave three products which were characterized, but did not lead to benzotriazepinone formation.